Arcutis Biotherapeutics

ARQT Mid Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$23.63

-1.95% today

52W: $11.86 – $31.77

52W Low: $11.86 Position: 59.1% 52W High: $31.77

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

18.48x

Forward Price/Earnings

P/S Ratio

7.79x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$2.9B

Market Capitalization

Revenue Growth

81.5%

YoY Revenue Growth

Profit Margin

-4.29%

Net profit margin

ROE

-9.3%

Return on Equity

Beta

1.77

Market sensitivity

Short Interest

15.57%

% of float sold short

Avg. Volume

1,422,101

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

None

8 analysts

Avg. Price Target

$34.75

+47.06% upside

Target Range

$33.00 – $36.00

About the Company

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 354 Exchange: NMS